BioInfra Co.,Ltd. Logo

BioInfra Co.,Ltd.

Offers cancer screening blood tests and provides CRO services to the pharmaceutical industry.

199730 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 흥덕중앙로 120 4층, 5층, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioInfra Co., Ltd. is a global healthcare and biotechnology company focused on advancing human health through innovative solutions for disease prevention and treatment. The company's core activities are centered on two primary business segments: diagnostics development and contract research organization (CRO) services. Its flagship product is a proprietary multi-biomarker blood test, a screening technology designed for the early detection of risk for eight major types of cancer. The company's CRO division provides comprehensive support to the pharmaceutical industry, offering services that include Phase 1 clinical trials, bioequivalence testing, immunoassays, and pharmaceutical quality inspections.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 763.0 KB
2025-06-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 83.8 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 754.8 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 30.2 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 18.1 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 103.0 KB
2025-03-14 00:00
Annual Report
사업보고서 (2024.12)
Korean 933.5 KB
2025-03-10 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.3 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 16.5 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 100.1 KB
2025-02-06 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB

Automate Your Workflow. Get a real-time feed of all BioInfra Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BioInfra Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.